Group One Trading
TSHA icon

Group One Trading’s Taysha Gene Therapies TSHA Stock Holding History

Group One Trading’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.47K Sell
1,000
-188,400
-99% -$876K ﹤0.01% 6752
2025
Q4 		$1.04M Buy
189,400
+186,400
+6,213% +$905K ﹤0.01% 2848
2025
Q3 		$9.81K Hold
3,000
– – ﹤0.01% 7182
2025
Q2 		$6.93K Buy
+3,000
New +$6.52K ﹤0.01% 6934
2024
Q4 		– Sell
-400
Closed -$804 – 7985
2024
Q3 		$804 Sell
400
-2,000
-83% -$4.39K ﹤0.01% 6322
2024
Q2 		$5.38K Sell
2,400
-500
-17% -$1.46K ﹤0.01% 5918
2024
Q1 		$8.32K Buy
+2,900
New +$6.04K ﹤0.01% 5965
2023
Q2 		– Sell
-4,000
Closed -$3.19K – 8232
2023
Q1 		$3.19K Hold
4,000
– – ﹤0.01% 6476
2022
Q4 		$9.04K Buy
+4,000
New +$8.1K ﹤0.01% 6069

Other funds holding TSHA

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Group One Trading's TSHA Position: Q1 2026 in Review

Group One Trading sold out of Taysha Gene Therapies (TSHA) in Q1 2026, closing a stake of 44,195 shares — an estimated $205K sold.

Group One Trading first reported a position in TSHA in Q4 2022 and held it in 6 quarters. The position peaked at $243K in Q4 2025. 191 funds tracked by Wall St. Rank hold TSHA as of Q1 2026.

  • Group One Trading reported no remaining Taysha Gene Therapies position as of Q1 2026 after selling out during the quarter.
  • Group One Trading sold 44,195 Taysha Gene Therapies shares in Q1 2026, an estimated $205K.
  • Group One Trading first reported a position in Taysha Gene Therapies in Q4 2022 and held it in 6 quarters.
  • Group One Trading's Taysha Gene Therapies position peaked at $243K in Q4 2025.
  • 191 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q1 2026.

Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.